ARA-290 16mg

▎ ARA-290 ƒe Dɔwɔɖoɖo

Dzɔtsoƒe: PubChem

Nusiwo kplɔ wo nɔewo ɖo: XEQLERALNSS Molekyulãwo ƒe Mɔfiame: C 51H 84N 16O21 Molekyulã ƒe Kpekpeme: 1257.3g/mol CAS Xexlẽdzesi:1208243-50-8 PubChem ƒe CID:91810664 Nya siwo sɔ kple wo nɔewo: Cibinetide

▎ ARA-290 Numekuku

Nukae nye numekuku si wowɔ le ARA-290 ŋu?  

ARA-290 ƒe ŋgɔyiyi dzɔ tso alesi wodzro erythropoietin (EPO) ƒe atikewɔwɔ ƒe ŋutete me. Dzɔdzɔmeŋutinunyalawo kpɔe be menye ɖeko EPO doa ʋumenugbagbeviɣidɔ ɖe ŋgɔ ko o, ke ewɔa dɔ siwo kpɔa lãmenugbagbeviwo ta abe dɔlékuiwutike kple apoptosis ene hã. Gake EPO ƒe ʋumenugbagbeviɣidɔ ate ŋu ana ʋu ƒe ʋeʋẽ kple afɔku bubuwo nadzi ɖe edzi, si ana be woagazãe le dɔléle siwo menye ʋusɔgbɔdɔ o dada me o. Be numekulawo nalé EPO ƒe lãmenugbagbeviwo takpɔkpɔ ƒe ŋusẽkpɔɖeamedziwo me ɖe asi esime woaƒo asa na eƒe ʋumenugbagbeviɣidɔ ƒe nugbegblẽ le ame ŋu la, wodze peptide siwo woɖe tso wo me ƒe wɔwɔme gɔme, si na wowɔ ARA-290.  

Esi wowɔ numekuku deto wu la, wokpɔ viɖe tɔxɛ siwo le ARA-290 ŋu abe peptide si mewɔa ʋumenugbagbeviɣidɔ o ene dze sii vivivi. Enaa dzesimɔ siwo tsia dzodzodzoetsitsi nu kple lãmenugbagbeviwo ɖɔɖɔɖo ƒe mɔnuwo wɔa dɔ to kadodo kple dzɔdzɔmenuwo ɖɔɖɔɖo ƒe xɔla (IRR) me, si ɖea ŋusẽkpɔɖeamedzi nyuiwo fiana le suklidɔ ƒe kuxiwo, ahɔhɔ̃mekawo ƒe dɔlélewo, kple ayiku ƒe abixɔxɔ dada me. Nusiwo ŋu woke ɖo siawo ɖo gɔmeɖoanyi na numekuku bubuwo kple ARA-290 zazã le atikewɔnyawo me eye wodo atikewɔwɔmɔnu yeye siwo wotu ɖe peptide siwo wokpɔ tso EPO me dzi la toto vɛ.  

Nukae nye ARA-290 ƒe dɔwɔwɔ ƒe mɔnu?  

Dɔlélenutsitsi ƒe Ŋusẽkpɔɖeamedzi: ARA-290 xea mɔ na dɔdzẽ ƒe cytokines ƒe dodo, si wɔnɛ be dɔdzẽ ƒe ŋuɖoɖowo dzi ɖena kpɔtɔna, abe alesi woɖee fia le dɔléle ƒe kpɔɖeŋu geɖe me ene. Le kpɔɖeŋu me, le sisiblisi ƒe kpɔɖeŋu si nye systemic lupus erythematosus (SLE) me la, eɖea dɔdzẽ ƒe cytokines IL-6, MCP-1, kple TNF-α ƒe ʋumenugbagbeviɣi dzi kpɔtɔna, si naa SLE ƒe dzesiwo nyona ɖe edzi{#Dahan, A,2016} (Dahan A, 2016). Le cisplatin-si wotsɔ wɔa ayiku me aɖi ƒe kpɔɖeŋu me la, eɖea pro-inflammatory cytokines TNFα, IL6, kple IL1β dzi kpɔtɔna, si ɖea ayiku ƒe dɔdzẽ dzi kpɔtɔna ^[2] (Ghassemi-Barghi N, 2023). Eƒe dɔlékuiwutike ate ŋu abia be woaɖo taɖodzinu na dzɔdzɔmenuwo ɖɔɖɔɖo ƒe xɔla (IRR), si nye erythropoietin xɔla kple β-common (CD131) xɔla ƒe heterodimer. IRR ƒe kadodo nana dzesimɔ siwo tsi tre ɖe dɔdzẽ ŋu siwo le anyime la wɔa dɔ, si wɔnɛ be dɔdzẽa dzi ɖena kpɔtɔna ^[1]..

Anti-Apoptotic Effect: ARA-290 xea mɔ na lãmenugbagbeviwo ƒe tsɔtsrɔ̃ eye wòdoa lãmenugbagbeviwo ƒe agbetsitsi ɖe ŋgɔ. Le suklidɔléla ƒe sisiblisi ƒe kpɔɖeŋu me la, etea ayiku ƒe ʋuka me lãmenugbagbeviwo ƒe tsɔtsrɔ̃ ɖe to eye wòɖea protease veviwo ƒe ɖeɖefia le apoptotic ƒe ɖoɖoa me dzi kpɔtɔna, si wɔnɛ be wòkpɔa ayiku takpɔkpɔ ƒe ŋusẽkpɔɖeamedziwo. Le ayiku me aɖi si cisplatin hena vɛ ƒe kpɔɖeŋuwo me la, eɖɔa protein siwo do ƒome kple apoptosis abe Bax kple Bcl-2 ene ƒe ɖeɖefia ɖo, exea mɔ na Caspase-3 ƒe dɔwɔwɔ, eɖea lãmenugbagbeviwo ƒe tsɔtsrɔ̃ dzi kpɔtɔna, eye wòɖea ayiku me lãmenugbagbeviwo ƒe gbegblẽ si cisplatin hena vɛ dzi kpɔtɔna ^[2]..  

Anti-Oxidative Effect: ARA-290 xea mɔ na oxidative stress ƒe nugbegblẽ eye wòɖea nusiwo gblẽa nu le ame ŋu abe reactive oxygen species (ROS) ene ƒe wɔwɔ dzi kpɔtɔna. Le suklidɔléla ƒe ayiku ƒe kpɔɖeŋu me la, etea ayiku ƒe domenyiŋusẽfianu ƒe ɖeɖefia ɖe to, eɖea ayiku me ROS ƒe agbɔsɔsɔ dzi kpɔtɔna, eye wòɖea malondialdehyde (MDA) ƒe ɖeɖefia dzi kpɔtɔna, si ɖea ayiku ƒe gbegblẽ si oxidative stress hena vɛ dzi kpɔtɔna. Le ʋukawo ƒe ʋuʋu ŋuti numekukuwo me la, dodokpɔ siwo wowɔ le vitro ɖee fia be ARA-290 xea mɔ na ROS wɔwɔ le macrophages me le dɔdzẽ ƒe nɔnɔmewo me, si ɖea oxidative stress ƒe nugbegblẽ le lãmenugbagbeviwo ŋu dzi kpɔtɔna.  

Dɔlélenutsiŋutete ƒe Lãmenugbagbeviwo ƒe Dɔwɔwɔ Dzi Kpɔkpɔ: ARA-290 kpɔa dɔlélenutsiŋutete ƒe lãmenugbagbeviwo abe macrophages ene ƒe dɔwɔwɔ dzi. Le vitro me la, exea mɔ na macrophages ƒe dɔdzẽ ƒe dɔwɔwɔ esime wòdoa woƒe phagocytic dɔwɔwɔ ɖe ŋgɔ ɖe apoptotic cells ŋu, kpena ɖe dɔlélenutsiŋutete ƒe homeostasis ŋu eye wòkɔa apoptotic cells ŋu be woaƒo asa na dɔdzẽ si woƒe ƒuƒoƒo hena vɛ (Dahan A, 2016). Le ʋukawo ƒe ʋuʋu ŋuti numekuku me la, ARA-290 xea mɔ na macrophage ƒe ʋuʋu kple foam cell ƒe wɔwɔ, si ɖea ami ƒe tsɔtsɔ ɖe ʋukawo me dzi kpɔtɔna eye wònaa ʋukawo ƒe ʋuʋu ƒe ŋgɔyiyi dzi ɖena kpɔtɔna.

Ahɔhɔ̃mekawo Takpɔkpɔ ƒe Mɔnu: Le ahɔhɔ̃mekawo ƒe ʋu ƒe sisi ƒe kpɔɖeŋu si wowɔ le sisiblisi me la, ARA-290 wɔa ahɔhɔ̃mekawo takpɔnu to β-common receptor (βCR) dzi. Eɖea ahɔhɔ̃mekawo ƒe tsɔtsrɔ̃ kple dɔdzẽ ƒe cytokine ƒe agbɔsɔsɔ dzi kpɔtɔna ŋutɔ le ahɔhɔ̃mekawo me, si wɔnɛ be ahɔhɔ̃mekawo ƒe dɔwɔwɔ nyona ɖe edzi. βCR-targeted siRNA dodo xea mɔ na ARA-290 ƒe ahɔhɔ̃mekawo takpɔkpɔ ƒe ŋusẽkpɔɖeamedziwo vevie, si ɖee fia be βCR wɔa akpa vevi aɖe le eƒe dɔwɔwɔ me ^[3]..  

Vevesesenutsitike ƒe Mɔnu: ARA-290 ate ŋu awɔ vevesesenutsitike ƒe ŋusẽkpɔɖeamedzi to vevesesenutsitike siwo le gota ƒe taɖodzinu tẽ me. Numekukuwo ɖee fia be exea mɔ na TRPV1 mɔ̃ ƒe dɔwɔwɔ koŋ eye wòɖea mɔ̃ɖaŋununya ƒe allodynia si capsaicin hena vɛ dzi kpɔtɔna, si fia be ARA-290 ate ŋu anye TRPV1 mɔ̃ ƒe mɔxenu yeye, si ana gɔmesese yeyewo nasu ame si hena vevesese dada ^[4]..  

Nukae nye ARA-290 ƒe dɔwɔwɔ?

Ahɔhɔ̃mekawo ƒe Dɔlélewo Dada

Vevesese dzi ɖeɖe kpɔtɔ kple Dzesiwo ƒe nyonyo: ARA-290 ɖea ahɔhɔ̃mekawo ƒe vevesese dzi kpɔtɔna nyuie, vevietɔ le dɔléle siwo ŋu ahɔhɔ̃mekawo ƒe dɔléle le abe suklidɔ kple sarcoidosis ene me. Le dɔdamɔnu dodokpɔ siwo wowɔ na sarcoidosis dɔnɔwo me la, ARA-290 na ahɔhɔ̃mekawo ƒe dɔléle kple autonomic nerve ƒe dzesiwo nyo ɖe edzi ŋutɔ, ena agbenɔnɔ ƒe nyonyome nyo ɖe edzi, eye wòɖe vevesese ƒe dzesiwo dzi kpɔtɔ, eye wòkpɔ ŋusẽ ma tɔgbe le suklidɔlélawo ƒe ahɔhɔ̃mekawo ŋu. Eƒe dɔwɔwɔ bia be wòabla ɖe dzɔdzɔme ɖɔɖɔɖomɔ̃ (IRR) ŋu, wòana dɔlékuiwutikewo kple lãmenugbagbeviwo ɖɔɖɔɖomɔwo nawɔ dɔ, aɖɔ ahɔhɔ̃mekawo ƒe dɔdzẽ ɖo, eye wòaɖe vevesese dzi akpɔtɔ ^{[1, 4].}.

 

Lãmetsiŋusẽ ƒe Gbugbɔgadzɔ Dodo Ðe Ŋgɔ: ARA-290 doa lãmekawo ƒe gbugbɔgadzɔ ɖe ŋgɔ. Le sarcoidosis dɔnɔwo gome la, ARA-290 dɔdamɔnu ŋkeke 28 tsiã ɖe enu na ŋkume ƒe lãmeka suewo gbugbɔgadzɔ, si ɖee fia be ŋutete le eŋu be wòaɖɔ lãmeka tɔxɛ aɖewo ɖo eye wòate ŋu ana ahɔhɔ̃mekawo ƒe dɔwɔwɔ nanyo ɖe edzi, togbɔ be mekpɔ ŋusẽ aɖeke ɖe lãkusi ƒe ka siwo le lãkusi me dzi o hã ^[1]..  

Nephrotoxicity dzi ɖeɖe kpɔtɔ  

Lãmenugbagbeviwo ƒe aɖi kple domenyiŋusẽfianu ƒe aɖi ƒe ɖiɖi: Le aɖuɖɔtoe me aɖi si cisplatin hena vɛ ƒe kpɔɖeŋuwo me la, ARA-290 ɖea aɖi si cisplatin hena vɛ kple domenyiŋusẽfianu ƒe aɖi dzi kpɔtɔna ŋutɔ, abe DNA ƒe gbegblẽ ƒe nɔnɔmewo dzi ɖeɖe kpɔtɔ le ɣletivimefakaka ƒe dodokpɔwo kple micronucleus ƒe dzidziɖedzi zi gbɔ zi geɖe me, lãmenugbagbeviwo ƒe domenyiŋusẽfianu takpɔkpɔ kple ayiku ƒe lãmenugbagbeviwo ƒe gbegblẽ dzi ɖeɖe kpɔtɔ ene ^{[1] .}.

 

Oxidative Stress kple Inflammation ƒe ɖoɖowɔwɔ: ARA-290 naa oxidative stress si cisplatin hena vɛ nyona ɖe edzi to malondialdehyde (MDA) kple ROS ƒe agbɔsɔsɔ dzi ɖeɖe kpɔtɔ kple antioxidant enzyme ƒe dɔwɔwɔ dzi ɖeɖe kpɔtɔ me. Eɖea ayiku ƒe dɔdzẽ hã dzi kpɔtɔna to pro-inflammatory cytokines (le kpɔɖeŋu me, TNF-α, IL-6, IL-1β) dzi ɖeɖe kpɔtɔ me, si kpɔa ame ta tso ayiku ƒe abi si cisplatin hena vɛ me ^[1]. .  

Mɔxexe ɖe Apoptosis nu: ARA-290 xea mɔ na apoptosis si cisplatin hena vɛ to domenyiŋusẽfianu kple protein siwo do ƒome kple apoptosis dzi kpɔkpɔ me (le kpɔɖeŋu me, Caspase-3 kple Bax ƒe ɖeɖefia dzi ɖeɖe kpɔtɔ, Bcl-2 ƒe ɖeɖefia dzi ɖeɖe kpɔtɔ), ayiku me lãmenugbagbeviwo ƒe agbetsitsi me léle ɖe asi kple ŋutete léle ɖe asi be woatsɔ ada ayiku me abi vevie ^{[1] .}.  

Blanuiléle ƒe Dzesiwo ƒe Nyonyome  

Nuwɔna si le abe Blanuiléle ene dzi ɖeɖe kpɔtɔ: Le nuteɖeamedzi fafɛ si womate ŋu agblɔ ɖi o si nɔa anyi didi kple hadome dziɖuɖu ƒe nuteɖeamedzi si nɔa anyi didi ƒe kpɔɖeŋu siwo wowɔ le sisiblisiwo me la, ARA-290 dodo gbesiagbe na nuwɔna si le abe blanuiléle ene nyo ɖe edzi, si sɔ kple blanuilélenutsitike si bɔ si woyɔna be fluoxetine. ARA-290 wɔ blanuilélenutsitike ƒe ŋusẽ evɔ mekpɔ ŋusẽ ɖe ʋumenugbagbevi dzĩ siwo le gota alo ʋumenugbagbevi dzĩwo dzi boo o ^[5]..  

Dɔlélenutsiŋutete ƒe Lãmenugbagbeviwo Kple Dzoxɔxɔ ƒe Ðoɖowɔwɔ: ARA-290 trɔa asi le dzidziɖedzi si nuteɖeamedzi atraɖii hena vɛ le CD11b+Ly6Ghi neutrophils kple CD11b+Ly6Chi monocytes ƒe dzidziɖedzi kple xexlẽme me le ƒumeŋuɖui kple ƒumeŋuɖui me, kpakple microglial ƒe dɔwɔwɔ, si ɖea blanuiléledzesiwo dzi kpɔtɔna to dɔlékuiwutikewo ƒe ŋusẽkpɔɖeamedziwo kple atikewɔwɔ yeyewo nana me mɔ siwo dzi woato akpɔ blanuiléle ^{[5] .}.  

Takpɔkpɔ Tso Suklidɔ ƒe Ayiku ƒe Gbegblẽ Me  

Mɔxexe Ðe Ayiku ƒe Tubular Epithelial Apoptosis Nu: ARA-290 xea mɔ na ayiku ƒe tubular epithelial cell apoptosis, si ɖea lãmenugbagbeviwo ƒe ku si ŋu wowɔ ɖoɖo ɖo dzi kpɔtɔna eye wòkpɔa ayiku ƒe lãmenugbagbeviwo ta.  

Ayiku ƒe Dɔwɔwɔ ƒe Dzesiwo ƒe Nyonyome: ARA-290 ɖea albumin ƒe dodo le aɖuɖɔ me dzi kpɔtɔna le suklidɔlélawo me, eɖea ayiku ƒe dɔléle ƒe gbegblẽ dzi kpɔtɔna, enaa ayiku ƒe dɔwɔwɔ nyona ɖe edzi, eye wòhea suklidɔ ƒe ayikudɔ ƒe ŋgɔyiyi ɖe megbe.  

Dɔléle si nye Systemic Lupus Erythematosus (SLE) ƒe Dɔdamɔnu .  

Autoantibody ƒe wɔwɔ kple dɔlélenutsiŋutete ƒe ƒuƒu ƒe mɔxexe: ARA-290 xea mɔ na serum antinuclear antibody (ANA) kple anti-double-stranded DNA antibody ƒe agbɔsɔsɔ vevie le SLE mice siwo wodo ɖa me, eɖea IgG kple C3 ƒe tsɔtsɔ ɖe ayiku me dzi kpɔtɔna, eɖea ayiku ƒe dzesiwo dzi kpɔtɔna, eye wònaa dɔlélea ƒe ŋgɔyiyi nyona ɖe edzi ^{[6] .}.  

Nɔnɔmetata 1 ARA290 ƒe atikewɔwɔ te dɔdzẽ ƒe ŋuɖoɖo ɖe te le pristane‐si wotsɔ wɔ SLE mice me. (A) Wokpɔ IL‐6, IL‐10, MCP‐1, IFN‐γ, TNF‐α, IL‐12p70 kple TGF‐β ƒe agbɔsɔsɔ le ʋumenugbagbeviɣi me le atikewɔwɔ si ŋu woƒo nu tsoe le Nɔnɔmetata 1 me megbe (n = 6). (B) Wotsi dɔdzẽ ƒe macrophage F4/80 ƒe gege ɖe lãme nu vevie to ARA 290 ƒe nudede eme me ne wotsɔe sɔ kple PBS dzi ɖuɖu. (C) Wodzidze dɔgbo kple ʋukawo ƒe kpekpeme le ARA290 ƒe atikewɔwɔ le SLE mice (n = 6) megbe. Nudzidzenu ƒe ʋuƒo tsi tre ɖi na 30 μm.

Dzɔtsoƒe:PubMed ^{[6] .}

Dɔdzẽ ƒe Cytokine ƒe Agbɔsɔsɔme Dzi Ðeɖe Akpɔtɔ: ARA-290 ɖea dɔdzẽ ƒe cytokines IL-6, MCP-1, kple TNF-α ƒe agbɔsɔsɔ si le ʋumenu me dzi kpɔtɔna le SLE mice me, si ɖea dɔdzẽ dzi kpɔtɔna eye wòɖea dɔléle ƒe dzesiwo dzi kpɔtɔna ^[6]..  

Apoptosis dzi ɖe kpɔtɔ: ARA-290 ɖea apoptotic cells ƒe xexlẽme dzi kpɔtɔna le ayiku me, ekpɔa ayiku me lãmenugbagbeviwo ta, eye wòxea mɔ na macrophages ƒe dɔdzẽ ƒe dɔwɔwɔ esime wòdoa woƒe phagocytosis na apoptotic cells ɖe ŋgɔ le vitro, ewɔa ɖoɖo ɖe dɔlélenutsiŋutete ŋu eye wòléa ŋutete ɖe asi na SLE dada ^{[6] .}.  

Atike Siwo Wozãna Le Atikewo Me ƒe Aɖi Dzi Ðeɖe Akpɔtɔ  

DNA ƒe Gbegblẽ dzi ɖeɖe kpɔtɔ: Le lãmenugbagbeviwo ƒe aɖi ƒe kpɔɖeŋu siwo doxorubicin (DOX) hena vɛ me la, ARA-290 ɖea DNA ƒe gbegblẽ si DOX hena vɛ dzi kpɔtɔna ŋutɔ, abe asike ƒe DNA ƒe alafa memamã dzi ɖeɖe kpɔtɔ le ɣletivimefakaka ƒe dodokpɔwo me kple micronucleus ƒe dzidziɖedzi, lãmenugbagbeviwo ƒe domenyiŋusẽfianu takpɔkpɔ kple atikewɔmɔnu ƒe nugbegblẽ le lãmenugbagbevi siwo sɔ ŋu dzi ɖeɖe kpɔtɔ ^{[7] .}.  

Oxidative Stress kple Inflammation dzi ɖeɖe kpɔtɔ: ARA-290 ɖea antioxidant enzyme ƒe dɔwɔwɔ ƒe gbegblẽ si DOX hena vɛ dzi kpɔtɔna, eɖea inflammation kple apoptosis dzi kpɔtɔna, eye wòkpɔa ame ta tso oxidative stress kple apoptosis si DOX hena vɛ me, si ate ŋu anye dzitodzito me lãmenugbagbeviwo hã, be wòaɖe nu gbegblẽ siwo dona tso atikewɔdɔlélawo dzi dzi akpɔtɔ ^{[7] .}.  

Mɔxexe Ðe Alzheimer Dɔlélea Nu Kple Edada  

Dɔléle ƒe Ŋgɔyiyi Blewu kple Sidzedze ƒe Dɔwɔwɔ Nyuitɔ: ARA-290 dodo kaba na APP/PS1 mice fẽwo (Alzheimer ƒe kpɔɖeŋu gbãtɔ) nana β-amyloid (Aβ) dɔléle ƒe ŋgɔyiyi dzi ɖena kpɔtɔna eye wònaa susu ƒe dɔwɔwɔ nyona ɖe edzi, si te gbe ɖe eƒe vevienyenye dzi na nudede eme kaba ^[8]..

Monocyte ƒe Dɔwɔwɔ Dzi Kpɔkpɔ: ARA-290 doa ŋusẽ Ly6C− monocyte ƒe hatsotso sue siwo le tsatsam ƒe dzidzi koŋ, enaa woƒe ʋu ƒe sisi ƒe agbɔsɔsɔ dzina ɖe edzi, edoa Aβ ɖeɖeɖa tso ahɔhɔ̃mekawo me ɖe ŋgɔ, eɖea ahɔhɔ̃ me Aβ ƒe agba dzi kpɔtɔna, eye wòhea dɔlélea ƒe ŋgɔyiyi ɖe megbe. Gake mewɔa dɔ boo le kpɔɖeŋu siwo wowɔ le eƒe nuwuwu (APP/PS1 mice siwo xɔ ƒe) me o, si te gbe ɖe alesi wòle vevie be woade nu nyaa me kaba dzi ^[8]..  

Suklidɔ ƒe Abi Dada Dodo Ðe Ŋgɔ

Abi ƒe Nututu Kabakaba: Le suklidɔ ƒe abi si wotso ƒe kpɔɖeŋu siwo streptozotocin hena vɛ me la, ARA-290 zazã le teƒea naa abi ƒe tutu kabakaba ŋutɔ, enaa abi ƒe gbugbɔgatu ƒe ɣeyiɣi nɔa kpuie, eye wònaa abi ƒe dɔyɔyɔ ƒe ŋutete nyona ɖe edzi ^[9]. .  

Lãmetsiŋusẽ Dzadzraɖo ƒe Dzesiwo Dzi Kpɔkpɔ: ARA-290 dzia collagen kple protein ƒe agbɔsɔsɔ ɖe edzi le lãkusi siwo wodzrana ɖo me, ewɔa ɖoɖo ɖe serum insulin, ʋumesukli, ami ƒe agbɔsɔsɔ, antioxidant ƒe nɔnɔme, kple pro-inflammatory cytokine ƒe agbɔsɔsɔ ŋu, si wɔnɛ be nuto sue aɖe si anyo na abi ƒe dɔyɔyɔ eye wònaa mɔnu yeyewo hena suklidɔlélawo ƒe afɔbidɛwo dada ^{[9] .}.  

Vevesese Dzi Ðeɖe Akpɔtɔ  

TRPV1 Mɔ̃ ƒe Dɔwɔna ƒe Mɔxexe: ARA-290 ɖea mɔ̃ɖaŋununya ƒe allodynia si capsaicin hena vɛ dzi kpɔtɔna to mɔxexe ɖe ɣeyiɣi kpui aɖe ƒe xɔla ƒe ŋutete vanilloid subtype 1 (TRPV1) mɔ̃ ƒe dɔwɔwɔ nu, si ɖoa taɖodzinu na peripheral nociceptors tẽ eye wònaa atikewɔwɔ ƒe taɖodzinu yeyewo kple mɔnu yeyewo hena vevesese dada ^[4]..  

Nyanuwuwuw  

ARA-290 nye polypeptide si wokpɔ tso EPO me si tsi tre ɖe dɔdzẽ ŋu, tsi tre ɖe apoptotic ŋu, kple esi tsi tre ɖe oxidative ŋu. Ate ŋu ada vevesese le suklidɔ kple sarcoidosis me, ado lãmekawo ƒe gbugbɔgadzɔ ɖe ŋgɔ, awɔ avu kple ayiku me aɖi, SLE, blanuiléle, eye wòaɖe vevesese dzi akpɔtɔ to tsitretsitsi ɖe TRPV1 ŋu me. Esi wònye be ŋutete le eŋu le Alzheimer ƒe dɔlélea ƒe nudede dɔa me le gɔmedzedzea me kple go bubuwo me ta la, mɔkpɔkpɔ gbadzawo le esi be wòazãe le atikewɔnyawo me.

Le Agbalẽŋlɔla La Ŋu

Nusiwo míeyɔ ɖe etame la katã nye esiwo ŋu Cocer Peptides wɔ numekuku le, trɔ asi le wo ŋu eye woƒo wo nu ƒu.

Dzɔdzɔmeŋutinunya ƒe Agbalẽŋlɔla

Al-Onaizi, Mohammed nye agbalẽnyala si si nunya deto le le atikewɔwɔ na nugbagbewo ƒe dɔwɔwɔ me. Kadodo kplikplikpli le eya kple suku kple numekuku dɔwɔƒe xɔŋkɔ geɖe, siwo dometɔ aɖewoe nye Dasman Suklidɔ Ŋuti Nusrɔ̃ƒe (DDI), Kuwait Yunivɛsiti, Laval Yunivɛsiti, Ɣetoɖoƒe Yunivɛsiti (Ɣetoɖoƒe Ontario Yunivɛsiti), kple Hebri Yunivɛsiti si le Yerusalem. Eƒe numekuku ƒe didiwo keke ta, eye wòku ɖe Neurosciences & Neurology, Biochemistry & Molecular Biology, Immunology, Psychiatry, kple nyati bubuwo le Life Sciences & Biomedicine me. Tohehe siawo le vevie ŋutɔ be woase amegbetɔ ƒe ŋutilã ƒe dɔwɔwɔ, dɔléle ƒe dɔwɔwɔ, kple atike yeyewo toto vɛ gɔme nyuie wu. Al-Onaizi, Mohammed ƒe numekukua kpɔ emetsonu veviwo le gɔmedzedze dzɔdzɔmeŋutinunya me eye wòna nukpɔsusu ƒe kpekpeɖeŋu veviwo kple mɔfiame ŋutɔŋutɔ na atikewɔnyawo kple atikewɔwɔ ŋuti numekuku.. Al-Onaizi, Mohammed is listed in the reference of citation [8].

▎ Nyayɔyɔ Siwo Sɔ

[1] Dahan A, Brines M, Niesters M, kple ame bubuwo. Taɖodzinu na dzɔdzɔmenuwo ɖɔɖɔɖodɔlékui be woatsɔ ada ahɔhɔ̃mekawo ƒe dɔléle[J]. Vevesese Ŋuti Nyatakakawo, 2016, 1 (1): e566.DOI: 10.1097 / PR9.0000000000000566.

[2] Ghassemi-Barghi N, Ehsanfar Z, Mohammadrezakhani O, kple ame bubuwo. Mɔ̃ɖaŋununya ƒe Mɔnu na Ametakpɔkpɔ ƒe Ŋusẽkpɔɖeamedzi si ARA290, si nye Ligand Tɔxɛ aɖe na Erythropoietin/CD131 Heteroreceptor, ɖe Cisplatin-Induced Nephrotoxicity, Apoptosis kple Dzoxɔxɔ Mɔwo ƒe Gomekpɔkpɔ Ŋu[J]. Dzoxɔxɔ, 2023, 46 (1): 342-358.DOI: 10.1007 / s10753-022-01737-7.

[3] Wang R, Yang Z, Huang Y, kple ame bubuwo. Erythropoietin‐derived peptide ARA290 nye domenɔla na ahɔhɔ̃mekawo takpɔkpɔ to $eta$‐common receptor dzi le mice siwo ŋu cerebral ischemic stroke le me[J]. CNS Ahɔhɔ̃ŋutinunya & Atikewɔwɔ, 2024,30. https://api.semanticscholar.org/CorpusID: 268414491. Eƒe lãmesẽnyawo gbɔ kpɔkpɔ.

[4] Zhang W, Yu G, Zhang M. ARA 290 ɖea dɔlélenutsiŋutete ƒe vevesese dzi kpɔtɔna to taɖodzinu TRPV1 mɔ̃ dzi: Dɔlélenutsiŋutete kple nociception dome ɖekawɔwɔ[J]. Peptides, 2016, 76: 73-79.DOI: 10.1016 / j. peptides.2016.01.003.

[5] Xu G, Zou T, Deng L, kple ame bubuwo. Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ðea Nuwɔna Siwo Le Abe Blanuiléle Si Le Nuteɖeamedzi Atraɖii Gbɔ Kple Dɔdzẽ Si Le Mice Me Dzi Ðena Ðe Edzi[J]. Liƒowo le Atikeŋutinunya me, 2022,13:896601.

DOI: 10.3389/fphar.2022.896601 ƒe ƒuƒoƒo.

[6] Huang B, Jiang J, Luo B, kple ame bubuwo. Peptide si woɖe tso erythropoietin me si mewɔa ʋumenugbagbeviɣidɔ o kpɔa sisiblisiwo ta tso systemic lupus erythematosus me[J]. Lãmenugbagbeviwo kple Molekyulãwo ƒe Atikewɔwɔ ƒe Agbalẽ, 2018,22 (7): 3330-3339.DOI: 10.1111 / jcmm.13608.

[7] Shokrzadeh M, Etebari M, Ghassemi-Barghi N. Peptide si woɖe tso erythropoietin me si menye ʋumenugbagbeviɣidɔ o si wowɔ, ARA290, ɖea doxorubicin hena domenyiŋusẽfianu ƒe aɖi kple oxidative stress dzi kpɔtɔna[J]. Aɖiŋutinunya le Vitro, 2020,66:104864.

DOI: 10.1016/j.tiv.2020.104864 ƒe agbalẽa me.

[8] Al-Onaizi M. A., Thériault P., Lecordier S., kple ame bubuwo. Monocyte ƒe tɔtrɔ kaba to non-erythropoietic peptide ARA 290 dzi ɖea dɔléle si le abe AD ene ƒe ŋgɔyiyi dzi kpɔtɔna[J]. Ahɔhɔ̃ ƒe Nuwɔna kple Dɔlélenutsiŋutete, 2022,99:363-382.

DOI:10.1016/j.bbi.2021.07.016.

[9] Mashreghi M, Bayrami Z, Sichani N, kple ame bubuwo. Numekuku aɖe si wowɔ le agbe me le abidada ƒe dɔwɔwɔ si le Specific ligand na innate repair receptor, ARA290, ŋu to suklidɔlélawo ƒe lã ƒe kpɔɖeŋu zazã me[M]. 2023.DOI:10.21203/rs.3.rs-2520194/v1.

NYATAKAKAWO KPLE NUSIWO WOTSƆ ƑE NYATAKAKA SIWO KAtã WOÐO LE NYATAKAKADZRAÐOƑE SIA ME LA KPLE NYATAKAKAWO kaka KPLEE NUFIAFIA ƑE TAÐOÐOWO KO.  

Wotrɔ asi le atike siwo wona le nyatakakadzraɖoƒe sia ŋu na numekuku le vitro ɖeɖeko. Wowɔa numekuku le vitro (Latingbe me: *le ahuhɔ̃e me*, si gɔmee nye le ahuhɔ̃e me) le amegbetɔ ƒe ŋutilã godo. Atike siawo menye atikewo o, United States ƒe Nuɖuɖu Kple Atike Ŋuti Dɔwɔƒe (FDA) meda asi ɖe wo dzi o, eye mele be woazã wo atsɔ axe mɔ ɖe atikewɔwɔ, dɔléle, alo dɔléle aɖeke nu, adae, alo adae o. Se de se vevie be woatsɔ atike siawo ade amegbetɔ alo lãwo ƒe ŋutilã me le mɔ ɖesiaɖe nu.